The COVID-19 pandemic has presented significant challenges for patients with hematologic malignancies, who are at an increased risk of severe illness and death from the virus. While vaccination against COVID-19 is a crucial tool in controlling the spread of the disease, there is limited information available on the safety and efficacy of these vaccines, antiviral and monoclonal antibodies used in either as pre-exposure or post-exposure prophylaxis or treatment of active infections in patients with hematologic malignancies. This Research Topic aims to address this knowledge gap by exploring the impact of COVID-19 therapies in this vulnerable patient population.
Further research is needed to better understand the safety and effectiveness of COVID-19 therapies in patients with hematologic malignancies, including those undergoing active treatment and those in remission. This Research Topic will bring together leading researchers and clinicians to present the latest findings on the impact of COVID-19 vaccination and target therapies in patients with hematologic malignancies. This will help to inform clinical decision-making and ensure that patients receive the best possible care.
The Research Topic welcomes original research articles, reviews, and perspectives that cover a range of sub-themes, including but not limited to:
- the immunogenicity and efficacy of COVID-19 vaccines/antivirals/monoclonal antibodies in patients with hematologic malignancies
- the impact of vaccination and therapy with antivirals or monoclonal antibodies on disease outcomes
management of treatment-related adverse events in this patient population.
- the ethical considerations surrounding COVID-19 vaccination in patients with hematologic malignancies, including issues related to access and equity.
- Effect of COVID-19 vaccines/antivirals/monoclonal antibodies on post-COVID condition
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
The COVID-19 pandemic has presented significant challenges for patients with hematologic malignancies, who are at an increased risk of severe illness and death from the virus. While vaccination against COVID-19 is a crucial tool in controlling the spread of the disease, there is limited information available on the safety and efficacy of these vaccines, antiviral and monoclonal antibodies used in either as pre-exposure or post-exposure prophylaxis or treatment of active infections in patients with hematologic malignancies. This Research Topic aims to address this knowledge gap by exploring the impact of COVID-19 therapies in this vulnerable patient population.
Further research is needed to better understand the safety and effectiveness of COVID-19 therapies in patients with hematologic malignancies, including those undergoing active treatment and those in remission. This Research Topic will bring together leading researchers and clinicians to present the latest findings on the impact of COVID-19 vaccination and target therapies in patients with hematologic malignancies. This will help to inform clinical decision-making and ensure that patients receive the best possible care.
The Research Topic welcomes original research articles, reviews, and perspectives that cover a range of sub-themes, including but not limited to:
- the immunogenicity and efficacy of COVID-19 vaccines/antivirals/monoclonal antibodies in patients with hematologic malignancies
- the impact of vaccination and therapy with antivirals or monoclonal antibodies on disease outcomes
management of treatment-related adverse events in this patient population.
- the ethical considerations surrounding COVID-19 vaccination in patients with hematologic malignancies, including issues related to access and equity.
- Effect of COVID-19 vaccines/antivirals/monoclonal antibodies on post-COVID condition
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
